

Physi	cian's	Ord	ers	

+)

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Patient Name
DOB
MRN
Physician
FIN

OCRELIZUMAB (OCREVUS), EVERY 6 MONTHS MAINTENANCE - ADULT, OUTPATIENT, INFUSION CENTER Page 1 of 5

Anticipated Infusion Date_____ ICD 10 Code with Description_____

Height	(cm) Weight	(kg) Allergies_		
Provider Specialty				
□ Allergy/Immunology	Infectious Disease		□ OB/GYN	Rheumatology
Cardiology	□ Internal Med/Family Pr	actice	□ Other	□ Surgery
Gastroenterology	Nephrology		Otolaryngology	Urology
Genetics	Neurology		Pulmonary	Wound Care
Site of Service				
SH Gerber	SH Lemmen Holton (G	iR)	SH Pennock	SH United Memorial
□ SH Helen DeVos (GF	R) 🗆 SH Ludington		SH Reed City	SH Zeeland
Treatment intent				
Conditioning	Curative		Mobilization	Supportive
Control	□Maintenance		□ Palliative	

Types: NON-ONCOLOGY SUPPORTIVE CARE, ONCOLOGY SUPPORTIVE CARE, ONCOLOGY SUPPORTIVE CARE 2, ONCOLOGY SUPPORTIVE CARE 3

Synonyms: OCRELIZUMAB, OCREVUS, MS, RELAPSING MS, PROGRESSIVE, PRIMARY MS, NEUROLOGY

Cycle 1	Cycle length: 168 days
Day 1	Perform every 1 day x1
Appointm	ent Requests
	ONCBCN CALCULATED LENGTH INFUSION APPOINTMENT REQUEST 1
	Interval: Once Occurrences: 1 Treatment Expected: S, Expires: S+365, 300 minutes (calculated), Schedule appointment at most 3 days before or at most 3 days after
Provider	Ordering Guidelines
	ONC PROVIDER REMINDER 18
	Interval: Once Occurrences: 1 Treatment
	Comments: OCRELIZUMAB (OCREVUS): Premedicate with methylprednisolone (125 mg IV) 30 minutes prior to each infusion, and an antihistamine (eg, diphenhydramine) 30 to 60 minutes prior each infusion; may also consider premedication with acetaminophen. Assess for infection; delay administration for active infection.
	Screen for hepatitis B virus in all patients (HBsAg and anti-HBc measurements) prior to treatment initiation. Refer to specialist as warranted by serology.
Safety Pa	arameters and Special Instructions
	ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 6
	Interval: Until discontinued Occurrences: 1 Treatment
	Comments: ocrelizumab (OCREVUS): Ensure the timing of previous dose and start of subsequent/maintenance doses is 6 months.

CONTINUED ON PAGE 2 →

NOTE: Epic Treatment/Therapy Plan Orders. To be scanned/attached to the appropriate Infusion Referral Order in Epic.



Patient Name
DOB
MRN
Physician
FINI

OCRELIZUMAB (OCREVUS), EVERY 6 MONTHS MAINTENANCE -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 2 of 5

Nursing Or	ders
	ONC NURSING COMMUNICATION 18
	Interval: Once Occurrences: 1 Treatment Comments: OCRELIZUMAB (OCREVUS): Premedicate patient prior to each infusion. Monitor for infusion reactions during infusion and observe for at least one hour after infusion is complete. If infusion reaction occurs, interrupt infusion, discontinue or decrease the rate, depending on the severity of the reaction.
	Administer though a dedicated IV line using a 0.2 or 0.22 micron in-line filter.
	First 2 infusions (300 mg dose): Begin infusion at 30 mL/hour; increase by 30 mL/hour every 30 minutes to a maximum rate of 180 mL/hour. Infusion duration is 2.5 hours or longer.
	Subsequent infusions (600 mg dose):
	Option 1: Begin infusion at 40 mL/hour; increase by 40 mL/hour every 30 minutes to a maximum rate of 200 mL/hour. Infusion duration is 3.5 hours or longer.
	Option 2 (if no previous serious infusion reactions to ocrelizumab): Begin infusion at 100 mL/hour for first 15 minutes; increase to 200 mL/hour for the next 15 minutes; increase to 250 mL/hour for the next 30 minutes; increase to 300 mL/hour for the remaining 60 minutes. Infusion duration is 2 hours or longer.
Nursing Or	ders
	ONC NURSING COMMUNICATION 100
Ŭ	Interval: Until discontinued Occurrences: 1 Treatment Comments: May Initiate IV Catheter Patency Adult Protocol.
Nursing Or	ders
۲	ONC NURSING COMMUNICATION 22
	Interval: Once Occurrences: 1 Treatment Comments: Observe patient in the infusion center for a minimum of 60 minutes following completion of infusion.
Vitals	
۲	VITAL SIGNS
U	Interval: PRN Occurrences: 1 Treatment Comments: Take vital signs at initiation and completion of infusion and as frequently as indicated by patient's symptoms.
Treatment	Parameters
۲	ONC MONITORING AND HOLD PARAMETERS 3
	Interval: Until discontinued Occurrences: 1 Treatment Comments: May proceed with treatment if hepatitis B core antibody and surface antigen labs have been resulted prior to the first dose, and the results are negative.
Pre-Medica	ations
\bigcirc	acetaminophen (TYLENOL) tablet
	Dose:Route: OralOnce for 1 dose325 mgOffset: 0 Hours500 mg650 mg1000 mg
	Instructions: Administer 30 to 60 minutes prior to infusion.

(+)

 $^+$



(+)

Patient Name
DOB
MRN
Physician

OCRELIZUMAB (OCREVUS), EVERY 6 MONTHS MAINTENANCE -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 3 of 5

Dro	Andiantiana
Pre-M	
	diphenhydrAMINE (BENADRYL) capsule Dose: Route: Oral Once for 1 dose 25 mg 50 mg
	Instructions: Administer 30 to 60 minutes prior to infusion.
Pre-N	/ledications
	methylPREDNISolone sodium succinate (SOLU-Medrol) injection
	Dose: 125 mg Route: Intravenous Once over 30 Minutes for 1 dose Offset: 0 Hours
	Instructions: For use in OP Infusion. Administer prior to infusion. Maximum infusion rate 40 mg/min.
	Refer to IV Push policy for maximum IV Push dose and rate. Do not administer doses greater than 125 mg by IV Push.
Media	cations
	ocrelizumab (OCREVUS) 600 mg in sodium chloride 0.9 % 520 mL IVPB
	Dose: 600 mg Route: Intravenous Titrate for 1 dose Offset: 30 Minutes
	Instructions: Subsequent infusions (600 mg dose): Begin infusion at 40 mL/hour; increase by 40 mL/hour every 30 minutes to a maximum rate of 200 mL/hour. Infusion duration is 3.5 hours or longer.
	Monitor for infusion reactions during infusion and observe for at least one hour after infusion is complete. If infusion reaction occurs, interrupt infusion, discontinue or decrease the rate, depending on the severity of the reaction.
	Administer through a dedicated IV line using a 0.2 or 0.22 micron in-line filter.
Cycle 2	Cycle length: 168 days
Day 1	Perform every 1 day x1
Арро	Intment Requests ONCBCN CALCULATED LENGTH INFUSION APPOINTMENT REQUEST
	Interval: Once Occurrences: 1 Treatment
	Expected: S, Expires: S+365, 300 minutes (calculated), Schedule appointment at most 3 days before or at most 3 days after
Provi	der Ordering Guidelines
	ONC PROVIDER REMINDER 18
	Interval: Once Occurrences: 1 Treatment
	Comments: OCRELIZUMAB (OCREVUS): Premedicate with methylprednisolone (125 mg IV) 30 minutes prior to each infusion, and an antihistamine (eg, diphenhydramine) 30 to 60 minutes prior each infusion; may also consider premedication with acetaminophen. Assess for infection; delay administration for active infection.
	Screen for hepatitis B virus in all patients (HBsAg and anti-HBc measurements) prior to treatment initiation. Refer to specialist as warranted by serology.

(+)

 $^+$



(+)

Patient Name
DOB
MRN
Physician
FIN

OCRELIZUMAB (OCREVUS), EVERY 6 MONTHS MAINTENANCE -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 4 of 5

Nursing O			
O	ONC NURSING CO	OMMUNICATION 18	
	Interval: Once	Occurrences: 1 Tre	atment
	for inf infusio	usion reactions during inf on is complete. If infusion	Premedicate patient prior to each infusion. Mor fusion and observe for at least one hour after reaction occurs, interrupt infusion, discontinue on the severity of the reaction.
	Admir	nister though a dedicated	IV line using a 0.2 or 0.22 micron in-line filter.
	mL/ho		: Begin infusion at 30 mL/hour; increase by 30 maximum rate of 180 mL/hour. Infusion duration
	Subse	equent infusions (600 mg	dose):
			mL/hour; increase by 40 mL/hour every 30 minu nour. Infusion duration is 3.5 hours or longer.
	at 100 minut) mL/hour for first 15 minues; increase to 250 mL/he	s infusion reactions to ocrelizumab): Begin infus utes; increase to 200 mL/hour for the next 15 our for the next 30 minutes; increase to 300 ninutes. Infusion duration is 2 hours or longer.
Nursing O	rders		
		OMMUNICATION 100	
e	Interval: Until disco		nces: 1 Treatment
	-		
	Comments: May I	nitiate IV Catheter Pateno	cy Adult Protocol
Nursing O	rders		
		OMMUNICATION 22	
Ŭ	Interval: Once	Occurrences: 1 Tre	atment
		rve patient in the infusion letion of infusion.	center for a minimum of 60 minutes following
) /itala			
Vitals	VITAL SIGNS		
	Interval: PRN	Occurrences: 1 Tre	atment
	Comments: Take		d completion of infusion and as frequently as
Pre-Medic	ations		
۲) acetaminophen (T	YLENOL) tablet	
	Dose: □ 325 mg □ 500 mg □ 650 mg □ 1000 mg	Route: Oral	Once for 1 dose Offset: 0 Hours
	Instructions:	60 minutes prior to infusi	

(+)

+



Patient Name
DOB
MRN
Physician

OCRELIZUMAB (OCREVUS), EVERY 6 MONTHS MAINTENANCE -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 5 of 5

		(BENADRYL) capsule	
	Dose: □ 25 mg □ 50 mg	Route: Oral	Once for 1 dose Offset: 0 Hours
	Instructions: Administer 30 to 6	60 minutes prior to infusion	
Pre-Me	dications		
	methylPREDNISol	one sodium succinate (S	OLU-Medrol) injection
	Dose: 125 mg	Route: Intravenous	Once over 30 Minutes for 1 dose Offset: 0 Hours
	Instructions: For use in OP Info	usion. Administer prior to in	fusion. Maximum infusion rate 40 mg/min.
	Refer to IV Push than 125 mg by IV		h dose and rate. Do not administer doses g
Medica	tions		
	ocrelizumab (OCR)	EVUS) 600 mg in sodium	chloride 0.9 % 520 mL IVPB
	Dose: 600 mg	Route: Intravenous	Titrate for 1 dose Offset: 30 Minutes
			infusion at 40 mL/hour; increase by 40 mL/ mL/hour. Infusion duration is 3.5 hours or
	is complete. If infu	usion reaction occurs, inter	and observe for at least one hour after infur rupt infusion, discontinue or decrease the ra
	depending on the	seventy of the reaction.	

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:		
TIME	DATE	TIME	DATE	TIME	DATE	Pager #
	Sign		R.N. Sign		Physician Print	Physician

+

+

+